PHARM - PHARM STOCK NEWS

Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR) has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will be held at NASDAQ, New York, on May 20, 2024.

Michael Levitan, VP of Investor Relations and Corporate Communications, will deliver a presentation at 09:30 EDT/15:30 CET. Investors interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their H.C. Wainwright representative.

Pharming Group has announced the early redemption of the remaining €1.9 million in 3.00% convertible bonds due 2025. Originally, €125 million in bonds were issued, but €123.1 million were repurchased by Pharming on 26 April 2024. The remaining bonds will be redeemed on 18 June 2024 at 100% of their principal amount, with accrued interest paid up to the redemption date. Bondholders have until 7 June 2024 to exercise their conversion rights at a price of €2.0028 per ordinary share. As of the latest trading session, Pharming's stock closed at €0.868.

Pharming Group N.V. reported a strong first quarter in 2024 with a 31% revenue increase to US$55.6 million driven by the U.S. launch of Joenja® and RUCONEST® growth. The company is on track to meet its 2024 revenue guidance of US$280-295 million. Pharming is actively finding more APDS patients and expanding leniolisib availability globally. Leniolisib clinical trials for pediatric and additional indications are progressing. The company refinanced convertible bonds to strengthen its financial position.

Pharming Group N.V. announces it will release its first quarter 2024 financial results on May 8, 2024. The company will present the preliminary unaudited report for the period ending March 31. Analysts and investors can join a conference call on the same day at 13:30 CEST/07:30 am EDT. To participate, registration is required. A live webcast will also be available for viewing.

Pharming Group N.V. is honored as an Industry Innovator at the NORD® 2024 Rare Impact Awards for commercializing Joenja® (leniolisib), the first-in-class medication for APDS. The FDA-approved treatment is the only one available for adult and pediatric patients with APDS, a rare immune system disorder. Pharming has successfully delivered the first shipments to patients in the U.S., marking a significant milestone in the treatment of rare diseases.

Pharming Group N.V. announces the successful repurchase of €123.1 million of outstanding €125 million convertible bonds due 2025, representing 98.5% of the total, at a final repurchase price of €100,000 per bond. The remaining outstanding bonds amount to €1.9 million, allowing the company to potentially early redeem them. HSBC and Jefferies served as Joint Dealer Managers for the repurchase.

Pharming Group N.V. announces the successful placement of €100 million convertible bonds due 2029, fully subscribed by institutional investors outside the US, Australia, Canada, Japan, and South Africa. The bonds will have a coupon of 4.50% per annum, with a conversion price set at €1.2271, representing a 37.5% premium. The proceeds will be used to repurchase outstanding convertible bonds due 2025, strengthening the company's financial position and flexibility for future business strategies.

Pharming Group N.V. announces the launch of a €100 million convertible bond offering due 2029 and the repurchase of €125 million convertible bonds due 2025. The New Bonds will be issued at a coupon rate of 4.50% per annum and are convertible into ordinary shares. The offering aims to strengthen Pharming's financial position and flexibility for future business strategies.

Pharming Group N.V. completes patient enrollment in Phase III trial of leniolisib tablets for children with APDS, aiming for regulatory approval in 2025.